Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

But basically it’s all about hitting the brain’s satiety centres. The new drugs make you feel full much more quickly and ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Weight loss drugs like Wegovy, Zepbound and Ozempic would be covered by Medicare and Medicaid under a Biden administration ...

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...